Users of Zinbryta, which has now been recalled from the market, could be at risk of developing autoimmune encephalopathy. Anyone who is diagnosed with autoimmune encephalopathy after taking Zinbryta could now have grounds to pursue a lawsuit against the manufacturers of the medication.

Even though the drug is now off the market, the side effects tied to this medication could still present as a problem in those patients who used Zinbryta previously. That’s why current users are advised to talk to their doctors about the possible risks.

If you think that you or a loved one could be at risk of brain-related problems like autoimmune encephalopathy after using this drug should make sure to set a medical appointment immediately.

Zinbryta Voluntary Recall

AbbVie and Biogen, the manufacturers of Zinbryta, announced in March 2018 that the medicine for multiple sclerosis would be voluntarily removed from the market after numerous reports were made about issues leading to inflammatory brain disorders.

One of the side effects reported by those patients who were affected included autoimmune encephalopathy. At least 12 cases of encephalitis tied to Zinbryta have been recorded worldwide and three of those cases have already been fatal.

Furthermore, Zinbryta has been linked to other critical side effects like serious skin reactions, liver failure and more.

In 2016, the FDA approved Zinbryta for treating multiple sclerosis. The primary reason for bringing Zinbryta on to the market was to help those patients who had had negative or no reaction to two or more other MS drugs.

However, problems with Zinbryta side effects, including autoimmune encephalopathy, have been tied to the MS drug since it was brought into the market in 2016. When the drug was initially approved, the FDA shared that they were aware of the complex safety profile of Zinbryta.

Zinbryta Risk

Many of the initial studies associated with Zinbryta had to do with the fact that it was recommended for those patients who had had no response to other types of MS drugs, meaning that the pool of potential patients was stronger.

However, a black box warning about the risks of severe liver injury and other immune mediated disorders was added to Zinbryta after the fact. This information was followed by a recommendation to only give the drug to patients who have not responded well to other multiple sclerosis drugs.

According to the lawsuits tied to Zinbryta at this point in time, patients allege that neither they nor their physicians were told about the risks of severe side effects, including autoimmune encephalopathy.

Autoimmune encephalopathy is tied to seizures, fatigue, muscle pain, irritability, headaches, stiff neck, vomiting or nausea, hallucination or delirium and mental confusion.

Although the drug has been taken off market, some patients might still be at risk of developing autoimmune encephalopathy down the road. Any patient who has taken this medication in the past should seek help in order to figure out whether or not grounds for a lawsuit exist.